165 related articles for article (PubMed ID: 37439934)
21. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
[TBL] [Abstract][Full Text] [Related]
22. Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI.
Chawla S; Wang S; Mohan S; Nasrallah M; Verma G; Brem S; O'Rourke DM; Wolf RL; Poptani H; Nabavizadeh SA
J Magn Reson Imaging; 2019 Jan; 49(1):184-194. PubMed ID: 29676844
[TBL] [Abstract][Full Text] [Related]
23. Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles.
Pons-Escoda A; Garcia-Ruiz A; Naval-Baudin P; Martinez-Zalacain I; Castell J; Camins A; Vidal N; Bruna J; Cos M; Perez-Lopez R; Oleaga L; Warnert E; Smits M; Majos C
Eur Radiol; 2024 Jan; ():. PubMed ID: 38282078
[TBL] [Abstract][Full Text] [Related]
24. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
[TBL] [Abstract][Full Text] [Related]
25. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
She D; Xing Z; Cao D
J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
[TBL] [Abstract][Full Text] [Related]
26. Machine learning based on multi-parametric magnetic resonance imaging to differentiate glioblastoma multiforme from primary cerebral nervous system lymphoma.
Nakagawa M; Nakaura T; Namimoto T; Kitajima M; Uetani H; Tateishi M; Oda S; Utsunomiya D; Makino K; Nakamura H; Mukasa A; Hirai T; Yamashita Y
Eur J Radiol; 2018 Nov; 108():147-154. PubMed ID: 30396648
[TBL] [Abstract][Full Text] [Related]
27. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of enhancement-perfusion mismatch in differentiation of CNS lymphomas from other enhancing malignant tumors of the brain.
Goyal P; Kumar Y; Gupta N; Malhotra A; Gupta S; Gupta S; Mangla M; Mangla R
Quant Imaging Med Surg; 2017 Oct; 7(5):511-519. PubMed ID: 29184763
[TBL] [Abstract][Full Text] [Related]
29. The role of dynamic susceptibility contrast-enhanced perfusion MR imaging in differentiating between infectious and neoplastic focal brain lesions: results from a cohort of 100 consecutive patients.
Floriano VH; Torres US; Spotti AR; Ferraz-Filho JR; Tognola WA
PLoS One; 2013; 8(12):e81509. PubMed ID: 24324699
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging.
Xi YB; Kang XW; Wang N; Liu TT; Zhu YQ; Cheng G; Wang K; Li C; Guo F; Yin H
Eur J Radiol; 2019 Mar; 112():59-64. PubMed ID: 30777220
[TBL] [Abstract][Full Text] [Related]
31. Differentiation of glioblastoma and primary central nervous system lymphomas using multiparametric diffusion and perfusion magnetic resonance imaging.
Hung ND; Anh NN; Minh ND; Huyen DK; Duc NM
Biomed Rep; 2023 Nov; 19(5):82. PubMed ID: 37881606
[TBL] [Abstract][Full Text] [Related]
32. Perfusion measurement in brain gliomas using velocity-selective arterial spin labeling: comparison with pseudo-continuous arterial spin labeling and dynamic susceptibility contrast MRI.
Qu Y; Kong D; Wen H; Ou X; Rui Q; Wang X; Lin DD; Qin Q; Wen Z
Eur Radiol; 2022 May; 32(5):2976-2987. PubMed ID: 35066634
[TBL] [Abstract][Full Text] [Related]
33. Three-dimensional arterial spin labeling imaging and dynamic susceptibility contrast perfusion-weighted imaging value in diagnosing glioma grade prior to surgery.
Ma H; Wang Z; Xu K; Shao Z; Yang C; Xu P; Liu X; Hu C; Lu X; Rong Y
Exp Ther Med; 2017 Jun; 13(6):2691-2698. PubMed ID: 28587332
[TBL] [Abstract][Full Text] [Related]
34. Diffuse Large B-Cell Epstein-Barr Virus-Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics.
Pons-Escoda A; García-Ruíz A; Naval-Baudin P; Grussu F; Viveros M; Vidal N; Bruna J; Plans G; Cos M; Perez-Lopez R; Majós C
AJNR Am J Neuroradiol; 2022 Nov; 43(11):1567-1574. PubMed ID: 36202547
[TBL] [Abstract][Full Text] [Related]
35. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.
Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH
Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709
[TBL] [Abstract][Full Text] [Related]
37. Multiparametric Framework Magnetic Resonance Imaging Assessment of Subtypes of Intracranial Germ Cell Tumors Using Susceptibility Weighted Imaging, Diffusion-Weighted Imaging, and Dynamic Susceptibility-Contrast Perfusion-Weighted Imaging Combined With Conventional Magnetic Resonance Imaging.
Li Y; Wang P; Zhang J; Li J; Chen L; Qiu X
J Magn Reson Imaging; 2022 Oct; 56(4):1232-1242. PubMed ID: 35278008
[TBL] [Abstract][Full Text] [Related]
38. Role of intra-tumoral vasculature imaging features on susceptibility weighted imaging in differentiating primary central nervous system lymphoma from glioblastoma: a multiparametric comparison with pathological validation.
Bhattacharjee R; Gupta M; Singh T; Sharma S; Khanna G; Parvaze SP; Patir R; Vaishya S; Ahlawat S; Singh A; Gupta RK
Neuroradiology; 2022 Sep; 64(9):1801-1818. PubMed ID: 35435463
[TBL] [Abstract][Full Text] [Related]
39. Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma.
Hu LS; Kelm Z; Korfiatis P; Dueck AC; Elrod C; Ellingson BM; Kaufmann TJ; Eschbacher JM; Karis JP; Smith K; Nakaji P; Brinkman D; Pafundi D; Baxter LC; Erickson BJ
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2242-9. PubMed ID: 26359151
[TBL] [Abstract][Full Text] [Related]
40. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]